Article (Scientific journals)
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Peyrin-Biroulet, Laurent; Ghosh, Subrata; Lee, Scott D et al.
2022In Alimentary Pharmacology and Therapeutics
Peer Reviewed verified by ORBi


Full Text
Effect of Risankinumab on heath-related quality of life of life of patients with Crohn s...phase 3 MOTIVATE ADVANCE and FORTIFY clinical trials_PPA.pdf
Author postprint (1.38 MB) Creative Commons License - Attribution, Non-Commercial

All documents in ORBi are protected by a user license.

Send to


Keywords :
Crohn’s disease; outcomes research; biologics
Abstract :
[en] BACKGROUND: Crohn's disease has a substantial negative impact on health-related quality of life (HRQoL). AIM: To examine the effects of risankizumab on HRQoL in Crohn's disease METHODS: We analysed data from patients with Crohn's disease from 12-week induction trials ADVANCE (N = 850) and MOTIVATE (N = 569) with risankizumab 600 mg or 1200 mg intravenous (IV) versus placebo IV and a 52-week maintenance trial FORTIFY (N = 462) with risankizumab 180 or 360 mg subcutaneous (SC) versus placebo SC. Outcomes included Inflammatory Bowel Disease Questionnaire (IBDQ), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), 36-item Short Form Health Survey (SF-36), EuroQol 5-Dimension-5-Level (EQ-5D-5L) and work productivity. The mean change and percentages of patients achieving clinically meaningful improvement in all outcomes were determined at weeks 12 and 52. RESULTS: At week 12, more patients in the risankizumab 600 or 1200 mg groups achieved IBDQ response than with placebo (ADVANCE: 70.2%, 75.5% vs. 47.8%, p ≤ 0.001; MOTIVATE: 61.7%, 68.5% vs. 48.2%, p ≤ 0.01) and FACIT-F response (ADVANCE: 51.3%, 48.0% vs. 35.7%, p ≤ 0.01; MOTIVATE: 44.2%, 49.1% vs. 33.7%, p < 0.05). These improvements persisted at week 52 with risankizumab maintenance treatment. Similar trends were observed for SF-36 physical and mental component summary scores, EQ-5D-5L and activity impairment within work productivity measures. CONCLUSIONS: Risankizumab induction therapy (600 or 1200 mg IV) led to clinically meaningful improvements in disease-specific and general patient-reported outcomes, including fatigue, in patients with moderate to severe Crohn's disease. These improvements were sustained after 52 weeks of risankizumab (180 or 360 mg SC) maintenance therapy.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Peyrin-Biroulet, Laurent;  Department of Gastroenterology, University of Lorraine, CHRU-Nancy, Nancy,  ; University of Lorraine, Inserm, NGERE, Nancy, France.
Ghosh, Subrata;  APC Microbiome Ireland, University College Cork, Cork, Ireland.
Lee, Scott D ;  University of Washington, Seattle, Washington, USA.
Lee, Wan-Ju;  AbbVie Inc., North Chicago, Illinois, USA.
Griffith, Jenny;  AbbVie Inc., North Chicago, Illinois, USA.
Wallace, Kori;  AbbVie Inc., North Chicago, Illinois, USA.
Berg, Sofie;  AbbVie Inc., North Chicago, Illinois, USA.
Liao, Xiaomei;  AbbVie Inc., North Chicago, Illinois, USA.
Panes, Julian;  Hospital Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Loftus, Edward V Jr ;  Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Language :
Title :
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Publication date :
20 October 2022
Journal title :
Alimentary Pharmacology and Therapeutics
Publisher :
Wiley, Oxford, Gb
Peer reviewed :
Peer Reviewed verified by ORBi
Funding number :
Commentary :
© 2022 AbbVie Inc. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Available on ORBi :
since 17 February 2023


Number of views
470 (3 by ULiège)
Number of downloads
290 (0 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi